Table 4.
VP manipulations and consummatory effects.
| Reference | VP Manipulation | System | Effects | Task | Result |
|---|---|---|---|---|---|
| Inui et al., 2007 | Bicuculline | GABA | GABA-A Antagonist | Consumption | Increase |
| Stratford et al., 1999 | Bicuculline | GABA | GABA-A Antagonist | Consumption | Increase |
| Stratford and Wirtshafter, 2012 | Lesion | NA | NA | Consumption induced by shell muscimol | Attenuated |
| Stratford and Wirtshafter, 2013 | Bicuculline | GABA | GABA-A Antagonist | Consumption | Increase |
| Stratford and Wirtshafter, 2013 | Bicuculline | GABA | GABA-A Antagonist | Consumption after LH lesion | Attenuated |
| Covelo et al. 2014 | Bicuculline | GABA | GABA-A Antagonist | Consumption of fat | Increase |
| Taha et al., 2009 | Muscimol | GABA | GABA-A Agonist | Consumption | Decrease |
| Smith et al., 2005 | Bicuculline | GABA | GABA-A Antagonist | Consumption | Increase |
| McAlonen et al., 1993 | Lesion | NA | NA | Consumption | No effect |
| Smith et al., 2005 | DAMGO | Opioid | Mu agonist | Consumption | Mixed |
| Smith et al., 2007 | DAMGO | Opioid | Mu agonist | Consumption | Increase |
| Harvey et al., 2002 | 3-PBC | GABA | A1 Mixed | Saccharin Consumption | Decrease |
| Shimura et al., 2006 | Muscimol | GABA | A Agonist | Consumption of Preferred saccharin | Decrease |
| Shimura et al., 2006 | Bicuculline | GABA | GABA-A Antagonist | Consumption of Preferred saccharin | Increase |
| Shimura et al., 2006 | CNQX | Glutamate | AMPA Antagonist | Consumption of Preferred saccharin | Decrease |
| Shimura et al., 2006 | DAMGO | Opioid | Mu agonist | Consumption of Preferred saccharin | Mixed |
| Shimura et al., 2006 | SCH-23390 | Dopamine | D2 Antagonist | Consumption of Preferred saccharin | Decrease |
| Shimura et al., 2006 | Sulpiride | Dopamine | D2 agonist | Consumption of Preferred saccharin | No effect |
| Shimura et al., 2006 | Muscimol | GABA | GABA-A Agonist | Consumption of Nonpreferred quinine | Decrease |
| Shimura et al., 2006 | Bicuculline | GABA | GABA-A Antagonist | Consumption of Nonpreferred quinine | Decrease |
| Shimura et al., 2006 | CNQX | Glutamate | AMPA Antagonist | Consumption of Nonpreferred quinine | No effect |
| Shimura et al., 2006 | DAMGO | Opioid | Mu agonist | Consumption of Nonpreferred quinine | Decrease |
| Shimura et al., 2006 | SCH-23390 | Dopamine | D2 Antagonist | Consumption of Nonpreferred quinine | No effect |
| Shimura et al., 2006 | Sulpiride | Dopamine | D2 agonist | Consumption of Nonpreferred quinine | No effect |
| Shimura et al., 2006 | Muscimol | GABA | GABA-A Agonist | Consumption of Water | Decrease |
| Shimura et al., 2006 | Bicuculline | GABA | GABA-A Antagonist | Consumption of Water | No effect |
| Shimura et al., 2006 | CNQX | Glutamate | AMPA Antagonist | Consumption of Water | No effect |
| Shimura et al., 2006 | DAMGO | Opioid | Mu agonist | Consumption of Water | Decrease |
| Shimura et al., 2006 | SCH-23390 | Dopamine | D2 Antagonist | Consumption of Water | No effect |
| Shimura et al., 2006 | Sulpiride | Dopamine | D2 agonist | Consumption of Water | No effect |
| Farrar et al., 2008 | Muscimol | GABA | GABA-A Agonist | Consumption during food self-administration | Mixed |
| Farrar et al., 2008 | Muscimol | GABA | GABA-A Agonist | Consumption of preferred substance | Mixed |
| Taha et al., 2009 | Muscimol | GABA | GABA-A Agonist | Consumption induced by Acb DAMGO | Blocked |
| Taha et al., 2009 | Lesion | NA | NA | Consumption induced by Acb DAMGO | No effect |
| Smith et al., 2007 | VP Naloxone & Acb DAMGO | Opioid | Antagonist | Consumption induced by Acb DAMGO | No effect |
| Smith et al., 2007 | VP DAMGO & Acb naloxone | Opioid | Mu agonist | Consumption induced by VP DAMGO | Decrease |
| Johnson et al., 1996b | Lesion | NA | NA | Responses during food self-administration | Decrease |
| Fletcher et al., 1998 | Amphetamine | Dopamine | Multiple | Responses during food self-administration with conditioned reinforcer | Increase |
| Fletcher et al., 1998 | Picrotoxin | GABA | GABA-A Antagonist | Food self-administration with conditioned reinforcer | Decrease |
| Smith et al., 2005 | Bicuculline | GABA | GABA-A Antagonist | Food carrying | Increase |
| Smith et al., 2005 | DAMGO | Opioid | Mu agonist | Food carrying | No effect |
| Inui et al., 2007 | Bicuculline | GABA | GABA-A Antagonist | Hedonic taste reactivity | Increase |
| Smith et al., 2005 | Bicuculline | GABA | GABA-A Antagonist | Hedonic taste reactivity | No effect |
| Smith et al., 2005 | DAMGO | Opioid | Mu agonist | Hedonic taste reactivity | Mixed |
| Smith et al., 2007 | DAMGO | Opioid | Mu agonist | Hedonic taste reactivity | Increase |
| Shimura et al., 2006 | Muscimol | GABA | GABA-A Agonist | Hedonic taste reactivity | Decrease |
| Shimura et al., 2006 | Bicuculline | GABA | GABA-A Antagonist | Hedonic taste reactivity | No effect |
| Shimura et al., 2006 | CNQX | Glutamate | AMPA Antagonist | Hedonic taste reactivity | No effect |
| Shimura et al., 2006 | DAMGO | Opioid | Mu agonist | Hedonic taste reactivity | No effect |
| Shimura et al., 2006 | SCH-23390 | Dopamine | D2 Antagonist | Hedonic taste reactivity | No effect |
| Inui et al., 2007 | Bicuculline | GABA | GABA-A Antagonist | Aversive taste reactivity | Decrease |
| Shimura et al., 2006 | Muscimol | GABA | GABA-A Antagonist | Aversive taste reactivity | Increase |
| Shimura et al., 2006 | Bicuculline | GABA | GABA-A Antagonist | Aversive taste reactivity | No effect |
| Shimura et al., 2006 | CNQX | Glutamate | AMPA Antagonist | Aversive taste reactivity | No effect |
| Shimura et al., 2006 | DAMGO | Opioid | Mu agonist | Aversive taste reactivity | No effect |
| Shimura et al., 2006 | SCH-23390 | Dopamine | D2 Antagonist | Aversive taste reactivity | No effect |
| Smith et al., 2007 | VP Naloxone & Acb DAMGO | Opioid | Antagonist | Taste reactivity induced by Acb DAMGO | Blocked |
| Smith et al., 2007 | VP DAMGO & Acb naloxone | Opioid | Antagonist | Taste reactivity induced by VP DAMGO | Blocked |
| Inui et al., 2007 | Bicuculline | GABA | GABA-A Antagonist | Taste aversion | Blocked |
Manipulation refers to an intra-VP injections or VP lesion, unless stated otherwise.